Published in J Clin Microbiol on November 01, 1999
Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations. J Virol (2010) 1.71
Evolution and diversity in human herpes simplex virus genomes. J Virol (2013) 1.35
Platinum(II) and palladium(II) complexes of pyridine-2-carbaldehyde thiosemicarbazone as alternative antiherpes simplex virus agents. Bioinorg Chem Appl (2007) 1.29
Utilization of microsatellite polymorphism for differentiating herpes simplex virus type 1 strains. J Clin Microbiol (2008) 0.97
Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol (2010) 0.88
HIV-associated disruption of tight and adherens junctions of oral epithelial cells facilitates HSV-1 infection and spread. PLoS One (2014) 0.85
Sequence-based methods for identifying epidemiologically linked herpes simplex virus type 2 strains. J Clin Microbiol (2006) 0.85
Worldwide circulation of HSV-2 × HSV-1 recombinant strains. Sci Rep (2017) 0.77
Molecular method development and establishment of a database for clinical and epidemiological herpes simplex virus 1 strain comparisons. J Clin Microbiol (2014) 0.77
Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Antimicrob Agents Chemother (2016) 0.76
Rad51 and Rad52 are involved in homologous recombination of replicating herpes simplex virus DNA. PLoS One (2014) 0.76
Genetic variability in the region encompassing reiteration VII of herpes simplex virus type 1, including deletions and multiplications related to recombination between direct repeats. Springerplus (2015) 0.75
Rapid and simple method for purification of nucleic acids. J Clin Microbiol (1990) 44.73
Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol (1968) 26.67
Anatomy of herpes simplex virus DNA. II. Size, composition, and arrangement of inverted terminal repetitions. J Virol (1975) 9.49
The structure and isomerization of herpes simplex virus genomes. Cell (1979) 6.79
Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1. Nucleic Acids Res (1986) 4.55
Nucleotide sequences of the joint between the L and S segments of herpes simplex virus types 1 and 2. J Gen Virol (1981) 3.70
Site-specific inversion sequence of the herpes simplex virus genome: domain and structural features. Proc Natl Acad Sci U S A (1981) 3.45
DNA sequence analysis of an immediate-early gene region of the herpes simplex virus type 1 genome (map coordinates 0.950 to 0.978). J Gen Virol (1982) 3.16
DNA sequence of an immediate-early gene (IEmRNA-5) of herpes simplex virus type I. Nucleic Acids Res (1982) 2.50
Quantitative analysis of genomic polymorphism of herpes simplex virus type 1 strains from six countries: studies of molecular evolution and molecular epidemiology of the virus. J Gen Virol (1994) 1.79
Antigenic differences between isolates of herpesvirus type 2. Intervirology (1974) 1.79
Reiterated sequences within the intron of an immediate-early gene of herpes simplex virus type 1. Nucleic Acids Res (1981) 1.42
A tandemly reiterated DNA sequence in the long repeat region of herpes simplex virus type 1 found in close proximity to immediate-early mRNA 1. J Virol (1984) 1.39
Herpes simplex virus isolation in chronic stromal keratitis: human and laboratory studies. Curr Eye Res (1987) 1.28
Strain specificity of clinical isolates of herpes simplex virus. Arch Ophthalmol (1980) 1.27
Robust amplification and ethidium-visible detection of the fragile X syndrome CGG repeat using Pfu polymerase. Am J Med Genet (1994) 1.19
Restriction endonuclease patterns of herpes simplex virus DNA: application to diagnosis and molecular epidemiology. Curr Top Microbiol Immunol (1983) 1.18
Comparative analysis of human cytomegalovirus a-sequence in multiple clinical isolates by using polymerase chain reaction and restriction fragment length polymorphism assays. J Clin Microbiol (1990) 1.16
Genomic comparison of herpes simplex virus type 1 isolates from Japan, Sweden and Kenya. J Gen Virol (1987) 1.05
Typing and strain differentiation of clinical herpes simplex virus type 1 and 2 isolates by polymerase chain reaction and subsequent restriction fragment length polymorphism analysis. Zentralbl Bakteriol (1994) 1.03
Isolation of novel herpes simplex virus type 1 derivatives with tandem duplications of DNA sequences encoding immediate-early mRNA-5 and an origin of replication. J Virol (1985) 1.02
Genomic characterization of two predominant genotypes of herpes simplex virus type 1. Arch Virol (1993) 1.02
Tandem repeated DNA in an intergenic region of herpes simplex virus type 1 (Patton). Gene (1984) 0.94
Reiterated sequences of herpes simplex virus type 1 (HSV-1) genome can serve as physical markers for the differentiation of HSV-1 strains. Arch Virol (1989) 0.92
7-Deazapurine containing DNA: efficiency of c7GdTP, c7AdTP and c7IdTP incorporation during PCR-amplification and protection from endodeoxyribonuclease hydrolysis. Nucleic Acids Res (1992) 0.92
Incorporation of 7-deaza dGTP during the amplification step in the polymerase chain reaction procedure improves subsequent DNA sequencing. DNA Seq (1990) 0.90
Diversity of naturally occurring Epstein-Barr virus revealed by nucleotide sequence polymorphism in hypervariable domains in the BamHI K and N subgenomic regions. J Gen Virol (1998) 0.88
Herpes simplex virus type 1 restriction fragment polymorphism determined using southern hybridization. Arch Virol (1984) 0.84
Recombinants are isolated at high frequency following in vivo mixed ocular infection with two avirulent herpes simplex virus type 1 strains. Arch Virol (1995) 0.84
Homogeneity and diversity of genome polymorphism in a set of herpes simplex virus type 1 strains classified as the same genotypic group. Arch Virol (1991) 0.83
A comparative analysis by restriction endonucleases of herpes simplex virus type 1 isolated in Japan and Kenya. J Infect Dis (1986) 0.82
Restriction enzyme fragment length polymorphisms of amplified herpes simplex virus type-1 DNA provide epidemiologic information. Diagn Microbiol Infect Dis (1994) 0.78
Preparation of herpes simplex virus type 1 genomic markers to differentiate strains of predominant genotypes. Arch Virol (1994) 0.78
Cosolvents facilitate DNA synthesis in the herpes simplex virus 1 unique short (Us) inverted repeat. J Virol Methods (1998) 0.77
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet (1998) 16.30
Emerging marine diseases--climate links and anthropogenic factors. Science (1999) 10.22
A pandemic warning? Nature (1997) 8.70
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill (2012) 7.96
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol (2000) 6.96
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill (2012) 4.95
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods (1998) 3.67
Diagnostic value of the polymerase chain reaction for Chlamydia detection as determined in a follow-up study. J Clin Microbiol (1991) 3.27
Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification. Appl Environ Microbiol (1992) 3.05
Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill (2013) 2.97
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Infectious RNA transcripts from Ross River virus cDNA clones and the construction and characterization of defined chimeras with Sindbis virus. Virology (1991) 2.57
Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis (1996) 2.51
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
Performance of a nonisotopic DNA probe for detection of Chlamydia trachomatis in urogenital specimens. J Clin Microbiol (1991) 2.21
Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies. Clin Diagn Lab Immunol (2000) 2.21
Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine (1998) 2.17
Reliability of methods for hepatitis B virus DNA detection. J Clin Microbiol (1995) 2.16
Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol (2000) 2.11
Haemorrhagic fever with renal syndrome. Lancet (1993) 2.09
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol (1997) 2.07
Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol (2000) 2.07
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Canine distemper virus from diseased large felids: biological properties and phylogenetic relationships. J Gen Virol (1996) 2.06
An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol (1999) 2.06
Uveitis masquerade syndromes. Ophthalmology (2001) 2.02
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med (1999) 2.01
Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol (2000) 1.95
Influenza types and patient population. Lancet (1995) 1.94
Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype. Lancet (2000) 1.87
A new surgical technique for deep stromal, anterior lamellar keratoplasty. Br J Ophthalmol (1999) 1.85
Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant (2007) 1.83
Virucidal effect of glycerol as used in donor skin preservation. Burns (1994) 1.81
Rapid and sensitive detection of Campylobacter spp. in chicken products by using the polymerase chain reaction. Appl Environ Microbiol (1992) 1.77
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol (2001) 1.70
Development of species-specific DNA probes for Campylobacter jejuni, Campylobacter coli, and Campylobacter lari by polymerase chain reaction fingerprinting. J Clin Microbiol (1993) 1.67
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother (2000) 1.66
Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis (1994) 1.65
Phylogeny of antigenic variants of avian coronavirus IBV. Virology (1989) 1.65
Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol (1997) 1.62
Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol (2000) 1.61
Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol (1997) 1.61
Identification of virus causing recent seal deaths. Nature (1988) 1.58
Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine (1996) 1.55
Prevalence and association between herpes simplex virus types 1 and 2-specific antibodies in attendees at a sexually transmitted disease clinic. Int J Epidemiol (2001) 1.53
PCBs are a health risk for humans and wildlife. Science (2000) 1.51
Influenza virus: a master of metamorphosis. J Infect (2000) 1.50
Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol (1993) 1.50
The hanta hunting study: underdiagnosis of Puumala hantavirus infections in symptomatic non-travelling leptospirosis-suspected patients in the Netherlands, in 2010 and April to November 2011. Euro Surveill (2014) 1.49
Canine distemper virus--a morbillivirus in search of new hosts? Trends Microbiol (1997) 1.49
Recommendations for the use of inactivated influenza vaccines and other preventive measures. Vaccine (2001) 1.47
Evaluation of Clearview and Magic Lite tests, polymerase chain reaction, and cell culture for detection of Chlamydia trachomatis in urogenital specimens. J Clin Microbiol (1993) 1.47
Mass die-Off of Caspian seals caused by canine distemper virus. Emerg Infect Dis (2001) 1.46
[Influenza pandemics: past and future]. Ned Tijdschr Geneeskd (1999) 1.42
The TNF-alpha system in heart failure and after heart transplantation: plasma protein levels, mRNA expression, soluble receptors and plasma buffer capacity. Eur Heart J (1999) 1.42
Herpes simplex virus type 1 (HSV-1)--induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1. Ann Neurol (2000) 1.42
Acute hepatitis C infection: an indication for alfa interferon therapy? Neth J Med (2000) 1.42
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis (1998) 1.42
International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods (1996) 1.41
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol (2000) 1.39
Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol (1998) 1.39
Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology (2000) 1.38
A quick surgical technique for deep, anterior lamellar keratoplasty using visco-dissection. Cornea (2000) 1.38
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol (2001) 1.38
Predicted membrane topology of the coronavirus protein E1. Biochemistry (1986) 1.38
Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol (1995) 1.38
[Two patients with acute hepatitis B from the same piercing salon]. Ned Tijdschr Geneeskd (1999) 1.38
The influence of phagocyte function on glomerular localization of aggregated IgM in rats. Clin Exp Immunol (1978) 1.38
The peplomer protein sequence of the M41 strain of coronavirus IBV and its comparison with Beaudette strains. Virus Res (1986) 1.37
Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. Intervirology (1983) 1.35
Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol (1990) 1.35
Attenuation of Sindbis virus neurovirulence by using defined mutations in nontranslated regions of the genome RNA. J Virol (1992) 1.34
Characterization of fastidious adenovirus types 40 and 41 by DNA restriction enzyme analysis and by neutralizing monoclonal antibodies. Virus Res (1989) 1.34
An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Arch Virol (1990) 1.34
Combination of reverse transcriptase PCR analysis and immunoglobulin M detection on filter paper blood samples allows diagnostic and epidemiological studies of measles. J Clin Microbiol (2001) 1.34
Detection, typing, and subtyping of enteric adenoviruses 40 and 41 from fecal samples and observation of changing incidences of infections with these types and subtypes. J Clin Microbiol (1993) 1.31
Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated from pneumonia patients in The Netherlands. Virology (2001) 1.30
Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper/cytotoxic and CD8+ cytotoxic T cell clones. J Immunol (1989) 1.29
Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis (1997) 1.29
New clues to the emergence of flu pandemics. Nat Med (1998) 1.28
Chimeric Sindbis-Ross River viruses to study interactions between alphavirus nonstructural and structural regions. J Virol (1996) 1.28
ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine (1999) 1.28
Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma. J Virol Methods (2000) 1.28
Antigen loading of MHC class I molecules in the endocytic tract. Traffic (2001) 1.27